Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for vascular retinopathy: macular structure and function study
2006-001678-25Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in retinal vascular disease, diabetic macular edema (DME), Vein occlusion (RVO) and 3 more, sponsored by Policlinico Gemelli. Primary endpoints: Safety, Change from baseline in visual acuity and 5 more. Started Jun 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
retinal vascular diseasediabetic macular edema (DME)Vein occlusion (RVO)cystoid macular edema (CME)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2006-001678-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001678-25.